Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Key Points

• The albumin-bound paclitaxel therapy did not show a significant difference in clinical efficacy between the two and three-week groups.
• The two-week treatment group demonstrated better tolerance and safety compared to the three-week group.
• Assessment of nab-PTX was performed across advanced pancreatic cancer cases with similar patient characteristics.
• Findings imply the potential for improved patient comfort with the shorter therapy duration.

Abstract